Overview

A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:
0

Participant gender:
All

Summary

The aim of this study was to determine the effect of intra-coronary administration of nicorandil on the prevention of lowering of coronary blood flow for high-risk plaque lesions defined as the high value of lipid core burden index in patients with coronary artery disease who require stent treatment.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Korea University Anam Hospital

Treatments:

Nicorandil

Criteria

Inclusion Criteria:

1. Over 19 years old

2. Patients who agree to the study plan and clinical follow-up plan, voluntarily decide
to participate in this study, and consent in writing to the consent to use information

3. Patients who underwent NIRS-IVUS guided coronary stent surgery for coronary artery
disease

Exclusion Criteria:

1. Patients with TIMI ≤ 2 before coronary intervention

2. Subjects with known hypersensitivity or contraindications to the following drugs or
substances: heparin, aspirin, clopidogrel, ticagrelor, prasugrel, rosuvastatin,
ezetimibe, evolocumab, lansoprazole, cobalt chromium, stainless steel nickel And
contrast agents (however, even a subject who is hypersensitive to contrast agents can
register if they can be controlled by steroids and pheniramine, except for known
anaphylaxis.)

3. Pregnant women, lactating women, or women of childbearing age who plan to become
pregnant during this study

4. Subjects who plan to have surgery to stop antiplatelet drugs within 6 months from
registration

5. Those whose surviving life is expected to be less than 1 year

6. Subjects who visited the hospital due to cardiogenic shock and are predicted to have
low survival probability based on medical judgment